Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fukui, Y.
Right arrow Articles by Motojima, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fukui, Y.
Right arrow Articles by Motojima, K.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 49, Issue 5 759-767, Copyright © 2000 by American Diabetes Association


ARTICLES

A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice

Y Fukui, S Masui, S Osada, K Umesono and K Motojima
Department of Biochemistry, School of Pharmaceutical Sciences, Toho University, Chiba, Japan.

Thiazolidinediones (TZDs) reduce insulin resistance in type 2 diabetes by increasing peripheral uptake of glucose, and they bind to and activate the transcriptional factor peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Studies have suggested that TZD-induced activation of PPAR-gamma correlates with antidiabetic action, but the mechanism by which the activated PPAR-gamma is involved in reducing insulin resistance is not known. To examine whether activation of PPAR-gamma directly correlates with antidiabetic activities, we compared the effects of 4 TZDs (troglitazone, pioglitazone, BRL-49653, and a new derivative, NC-2100) on the activation of PPAR-gamma in a reporter assay, transcription of the target genes, adipogenesis, plasma glucose and triglyceride levels, and body weight using obese KKAy mice. There were 10- to 30-fold higher concentrations of NC-2100 required for maximal activation of PPAR-gamma in a reporter assay system, and only high concentrations of NC-2100 weakly induced transcription of the PPAR-gamma but not PPAR-alpha target genes in a whole mouse and adipogenesis of cultured 3T3L1 cells, which indicates that NC-2100 is a weak PPAR-gamma activator. However, low concentrations of NC-2100 efficiently lowered plasma glucose levels in KKAy obese mice. These results strongly suggest that TZD-induced activation of PPAR-gamma does not directly correlate with antidiabetic (glucose-lowering) action. Furthermore, NC-2100 caused the smallest body weight increase of the 4 TZDs, which may be partly explained by the finding that NC-2100 efficiently induces uncoupling protein (UCP)-2 mRNA and significantly induces UCP1 mRNA in white adipose tissue (WAT). NC-2100 induced UCP1 efficiently in mesenteric WAT and less efficiently in subcutaneous WAT, although pioglitazone and troglitazone also slightly induced UCP1 only in mesenteric WAT. These characteristics of NC-2100 should be beneficial for humans with limited amounts of brown adipose tissue.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
M. C. Carmona, K. Louche, B. Lefebvre, A. Pilon, N. Hennuyer, V. Audinot-Bouchez, C. Fievet, G. Torpier, P. Formstecher, P. Renard, et al.
S 26948: a New Specific Peroxisome Proliferator Activated Receptor {gamma} Modulator With Potent Antidiabetes and Antiatherogenic Effects
Diabetes, November 1, 2007; 56(11): 2797 - 2808.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
Y. Si, S. Palani, A. Jayaraman, and K. Lee
Effects of forced uncoupling protein 1 expression in 3T3-L1 cells on mitochondrial function and lipid metabolism
J. Lipid Res., April 1, 2007; 48(4): 826 - 836.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
E. Burgermeister, A. Schnoebelen, A. Flament, J. Benz, M. Stihle, B. Gsell, A. Rufer, A. Ruf, B. Kuhn, H. P. Marki, et al.
A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-{gamma} (PPAR{gamma}) Recruits PPAR{gamma}-Coactivator-1{alpha}, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro
Mol. Endocrinol., April 1, 2006; 20(4): 809 - 830.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
I. Bogacka, B. Ukropcova, M. McNeil, J. M. Gimble, and S. R. Smith
Structural and Functional Consequences of Mitochondrial Biogenesis in Human Adipocytes in Vitro
J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6650 - 6656.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith
Pioglitazone Induces Mitochondrial Biogenesis in Human Subcutaneous Adipose Tissue In Vivo
Diabetes, May 1, 2005; 54(5): 1392 - 1399.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
H. Sell, J. P. Berger, P. Samson, G. Castriota, J. Lalonde, Y. Deshaies, and D. Richard
Peroxisome Proliferator-Activated Receptor {gamma} Agonism Increases the Capacity for Sympathetically Mediated Thermogenesis in Lean and ob/ob Mice
Endocrinology, August 1, 2004; 145(8): 3925 - 3934.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Tiraby, G. Tavernier, C. Lefort, D. Larrouy, F. Bouillaud, D. Ricquier, and D. Langin
Acquirement of Brown Fat Cell Features by Human White Adipocytes
J. Biol. Chem., August 29, 2003; 278(35): 33370 - 33376.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. Laplante, H. Sell, K. L. MacNaul, D. Richard, J. P. Berger, and Y. Deshaies
PPAR-{gamma} Activation Mediates Adipose Depot-Specific Effects on Gene Expression and Lipoprotein Lipase Activity: Mechanisms for Modulation of Postprandial Lipemia and Differential Adipose Accretion
Diabetes, February 1, 2003; 52(2): 291 - 299.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. Sato, C. Kuriki, Y. Fukui, and K. Motojima
Dual Promoter Structure of Mouse and Human Fatty Acid Translocase/CD36 Genes and Unique Transcriptional Activation by Peroxisome Proliferator-activated Receptor alpha and gamma Ligands
J. Biol. Chem., May 3, 2002; 277(18): 15703 - 15711.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
H. S. Camp, A. Chaudhry, and T. Leff
A Novel Potent Antagonist of Peroxisome Proliferator-Activated Receptor {{gamma}} Blocks Adipocyte Differentiation But Does Not Revert the Phenotype of Terminally Differentiated Adipocytes
Endocrinology, July 1, 2001; 142(7): 3207 - 3213.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J.-H. Kim, T. M. Lewin, and R. A. Coleman
Expression and Characterization of Recombinant Rat Acyl-CoA Synthetases 1, 4, and 5. SELECTIVE INHIBITION BY TRIACSIN C AND THIAZOLIDINEDIONES
J. Biol. Chem., June 29, 2001; 276(27): 24667 - 24673.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2000 by the American Diabetes Association.